Omeros (Omeros) Notes Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Notes Receivable?

Omeros's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Omeros Notes Receivable Historical Data

The historical data trend for Omeros's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Notes Receivable Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Omeros Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Omeros Notes Receivable Related Terms

Thank you for viewing the detailed overview of Omeros's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (Omeros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Executives

Demopulos Gregory A Md	director, 10 percent owner, officer: Chairman, CEO & President	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen	officer: VP Finance and CAO	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo	officer: See Remarks	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol	director	201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon	officer: VP Patent and General Counsel	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet	director	1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347